Therapeutic Duplications

1. A patient's profile shows active prescriptions for both ibuprofen and naproxen. What should the pharmacy technician do?

Ibuprofen and naproxen are both NSAIDs, so filling both increases the risk of GI bleeding and kidney injury without added benefit. A therapeutic duplication like this requires pharmacist review, not technician-level resolution.

2. Which scenario represents a therapeutic duplication that a pharmacy technician should flag for the pharmacist?

Lisinopril (an ACE inhibitor) and losartan (an ARB) both act on the renin-angiotensin system, and combining them is a duplication that increases the risk of hyperkalemia and hypotension without proven added benefit. The other pairings treat unrelated conditions through unrelated mechanisms.

3. A patient profile shows both omeprazole and pantoprazole prescribed by two different physicians. What is the technician's correct next step?

Omeprazole and pantoprazole are both proton pump inhibitors; taking both provides no additional acid suppression benefit and should be flagged for pharmacist intervention, regardless of which prescriber wrote each one.

4. Which of the following is an example of therapeutic duplication?

Metoprolol and atenolol are both beta blockers; taking both duplicates the mechanism of action and increases risk of bradycardia and hypotension. The other combinations pair a beta blocker with a drug from an unrelated class, which is not duplication.

5. A patient's profile shows active prescriptions for sertraline (from their primary care physician) and fluoxetine (from a psychiatrist). What does this represent?

Sertraline and fluoxetine are both SSRIs; combining them is a duplication that increases the risk of serotonin syndrome. Different prescribers writing the orders does not make the combination safe — this is exactly the kind of gap in care coordination that pharmacy duplication checks are designed to catch.

6. Why is checking for therapeutic duplications an important part of a pharmacy technician's data entry role?

Patients frequently see multiple prescribers (PCP, specialists, urgent care) who may not have visibility into each other's prescribing. The pharmacy's medication profile is often the only place where duplicate or overlapping therapy from the same drug class gets caught before it reaches the patient.

7. A patient is prescribed both glipizide and glyburide. What class-level issue does this represent?

Glipizide and glyburide are both sulfonylureas that stimulate insulin release; taking both increases the risk of hypoglycemia without added glycemic benefit. This is a duplication within the same drug class, not merely an interaction between different classes.

8. When the pharmacy computer system flags a therapeutic duplication during order entry, what is the technician's appropriate action?

Clinical judgment calls, including whether to override a duplication alert, are outside a technician's scope of practice. The correct action is always to route the alert to the pharmacist for evaluation, not to make the clinical decision independently.

9. A patient's profile shows both a fentanyl patch and an oxycodone immediate-release prescription. Is this a therapeutic duplication?

Pairing a long-acting opioid (fentanyl patch) with a short-acting opioid for breakthrough pain (oxycodone IR) is a standard, intentional pain-management strategy — not a duplication. True duplications involve two products serving the identical role, not a base + breakthrough combination. This still warrants normal opioid safety checks, but it is not flagged as duplicate therapy.

10. Which pair of medications represents a true therapeutic duplication?

Amlodipine and nifedipine are both dihydropyridine calcium channel blockers, so prescribing both duplicates the mechanism and increases the risk of hypotension and edema. The other pairings combine a calcium channel blocker with drugs from unrelated classes used for different (or complementary) purposes.

1. A patient fills prescriptions for both diphenhydramine (for sleep) and doxylamine (for allergies) from two different pharmacies. What concern does this raise?

Diphenhydramine and doxylamine are both first-generation antihistamines, and combining them compounds sedation and anticholinergic side effects (dry mouth, confusion, urinary retention) even though the patient is using them for different stated purposes. This is exactly the kind of duplication pharmacy systems are designed to catch across different fill locations.

2. Why might therapeutic duplication checks be especially important for elderly patients?

Older adults commonly see multiple specialists, increasing the chance of unintentional duplicate prescribing, and they are more vulnerable to the cumulative effects of duplicated sedatives, anticholinergics, or antihypertensives — including falls, confusion, and hypotension.

3. A patient is prescribed both esomeprazole (from a GI specialist) and famotidine (from their PCP) for reflux symptoms. What does this represent?

Even though esomeprazole (a PPI) and famotidine (an H2 antagonist) work through different mechanisms, they serve the same therapeutic purpose of acid suppression for the same condition. This kind of cross-class overlap still counts as a therapeutic duplication and should be flagged for pharmacist review.

4. A patient's profile shows two different opioid prescriptions from two different prescribers, filled the same week. Besides the duplication concern, what federal/state tool might a pharmacist also check?

For controlled substances specifically, pharmacists cross-check the state's Prescription Drug Monitoring Program (PDMP) to see prescriptions filled at other pharmacies — a key tool for catching duplicate opioid or benzodiazepine therapy that a single pharmacy's own system might not otherwise reveal.

5. A patient's profile shows simvastatin prescribed by one doctor and rosuvastatin prescribed by another. What is the correct technician response?

Technicians enter prescriptions as written and rely on the pharmacy system's clinical decision support to flag same-class duplications like two statins; the technician's job is accurate data entry and appropriate escalation, not independently deciding which prescription is correct or contacting prescribers to cancel orders.

6. Which of these best explains why therapeutic duplication is a distinct concept from a drug-drug interaction?

Therapeutic duplication is about redundant therapy — two medications serving the same clinical purpose, which increases side-effect risk through additive effect, not necessarily through direct chemical interaction. A drug-drug interaction, by contrast, is about one drug altering another's absorption, metabolism, or effect, even from an unrelated class.

7. A patient's profile shows two multivitamin products from different manufacturers along with a separate calcium supplement. Does this raise a duplication concern?

While often lower-risk than prescription duplications, overlapping OTC products can still cause excess intake of fat-soluble vitamins or minerals like calcium, so a thorough profile review includes OTC and supplement products the patient reports using, not prescriptions alone.

8. A pharmacy technician notices a patient has active prescriptions for both citalopram and trazodone. Is this necessarily a duplication requiring pharmacist review?

Citalopram (an SSRI) and trazodone both affect serotonin activity. Even when trazodone is prescribed off-label at low doses for sleep, the combination still carries increased serotonergic risk and should be flagged for pharmacist evaluation rather than assumed safe based on the stated indication.

9. What is the primary patient-safety reason pharmacy software includes automated therapeutic duplication alerts at the point of data entry?

Automated duplication alerts exist because redundant therapy — most often the result of multiple prescribers acting without full visibility into each other's orders — can produce additive toxicity (like excess sedation, bleeding risk, or hypoglycemia) that neither the prescriber nor the patient may recognize until the pharmacy's system catches it.

10. A patient's profile shows both alprazolam and clonazepam prescribed by two different providers. What does this represent?

Alprazolam and clonazepam are both benzodiazepines; taking both duplicates the sedative/anxiolytic mechanism and compounds the risk of oversedation and respiratory depression, especially if combined with opioids. Differing half-lives do not make concurrent use of two benzodiazepines safe.

1. Which of the following best describes how a pharmacy technician should handle a therapeutic duplication alert that seems clinically justified (e.g., a tapering cross-titration between two similar antidepressants)?

Even when a duplication looks like a plausible cross-titration, the clinical judgment of whether it's intentional and safe belongs to the pharmacist, not the technician. The correct workflow is the same regardless of how reasonable the duplication appears: escalate, don't resolve independently.

2. A patient is prescribed both loratadine (daily, from their PCP) and cetirizine (as needed, from an allergist). What does this represent?

Loratadine and cetirizine are both second-generation antihistamines; even with different dosing schedules (daily vs. PRN), routine use of both provides no additive allergy relief and should be flagged as a duplication for pharmacist review.